Last reviewed · How we verify
Losmapimod for single dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Losmapimod for single dose (Losmapimod for single dose) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Losmapimod for single dose TARGET | Losmapimod for single dose | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Losmapimod for single dose CI watch — RSS
- Losmapimod for single dose CI watch — Atom
- Losmapimod for single dose CI watch — JSON
- Losmapimod for single dose alone — RSS
Cite this brief
Drug Landscape (2026). Losmapimod for single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/losmapimod-for-single-dose. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab